Clinical, cellular, and molecular aspects in the pathophysiology of rosacea

Journal of Investigative Dermatology Symposium Proceedings

Volumn 15, Issue 1, 2011, Pages 2-11

  Steinhoff, Martin ^a,b   Buddenkotte, Jörg ^b   Aubert, Jerome ^c   Sulk, Mathias ^b   Novak, Pawel ^b   Schwab, Verena D ^b   Mess, Christian ^b   Cevikbas, Ferda ^a   Rivier, Michel ^c   Carlavan, Isabelle ^c   Déret, Sophie ^c   Rosignoli, Carine ^c   Metze, Dieter ^b   Luger, Thomas A ^b   Voegel, Johannes J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Galderma R and D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CD1 ANTIGEN; CD20 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD79 ANTIGEN; CD8 ANTIGEN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 1; INTERLEUKIN 26; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 8; LACTOFERRIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NUCLEAR FACTOR; PODOPLANIN; PROTEINASE; RANTES; TOLL LIKE RECEPTOR 2; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRYPTOPHAN; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VASCULOTROPIN; VIMENTIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE CLASSIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; LYMPH VESSEL; PATHOPHYSIOLOGY; ROSACEA; SUN EXPOSURE; TEMPERATURE; VASODILATATION;

EID: 80955166523     PISSN: 10870024     EISSN: 15291774     Source Type: Journal    
DOI: 10.1038/jidsymp.2011.7     Document Type: Conference Paper

References (74)

1. Abram K, Silm H, Maaroos HI et al. (2010a) Risk factors associated with rosacea. J Eur Acad Dermatol Venereol 24:565-71
2. Abram K, Silm H, Oona M (2010b) Prevalence of rosacea in an Estonian working population using a standard classification. Acta Derm Venereol 90:269-73
3. Akamatsu H, Oguchi M, Nishijima S et al. (1990) The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 282:449-54 (Pubitemid 20350067)
4. Aloi F, Tomasini C, Soro E et al. (2000) The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol 42:468-72 (Pubitemid 30470355)
5. Aroni K, Tsagroni E, Kavantzas N et al. (2008) A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 300:125-31
6. Aubdool AA, Brain SD (2011) Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc 15:33-9
7. Bakar O, Demircay Z, Yuksel M et al. (2007) The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 32:197-200 (Pubitemid 46233028)
8. Bamford JT (2001) Rosacea: current thoughts on origin. Semin Cutan Med Surg 20:199-206 (Pubitemid 32927782)
9. Bender A, Zapolanski T, Watkins S et al. (2008) Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Exp Dermatol 17:752-60
10. Caterina MJ, Schumacher MA, Tominaga M et al. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816-24 (Pubitemid 27462969)
11. Chujo S, Shirasaki F, Kondo-Miyazaki M et al. (2009) Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol 220:189-95
12. Craige H, Cohen JB (2005) Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 53:881-4 (Pubitemid 41501387)
13. Craik CS, Page MJ, Madison EL (2011) Proteases as therapeutics. Biochem J 435:1-16
14. Crawford GH, Pelle MT, James WD (2004) Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 51:327-41 (Pubitemid 39178655)
15. Dahl MV, Rosas AJ, Schlievert PM (2004) Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 50:266-72 (Pubitemid 38174287)
16. Earley S (2010) Vanilloid and melastatin transient receptor potential channels in vascular smooth muscle. Microcirculation 17:237-49
17. Eslami A, Gallant-Behm CL, Hart DA et al. (2009) Expression of integrin alphavbeta6 and TGF-beta in scarless versus scar-forming wound healing. J Histochem Cytochem 57:543-57
18. Flint ID, Wilkin JK (1994) Acquired persistent erythematous patch on the neck. Acquired nevus flammeus. Arch Dermatol 130:509, 512
19. Gallo R, Drago F, Paolino S et al. (2010) Rosacea treatments: what's new and what's on the horizon? Am J Clin Dermatol 11:299-303
20. Gerber PA, Buhren BA, Steinhoff M et al. (2011) Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc 15:40-7
21. Gibbons CH, Wang N, Freeman R (2010) Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann Neurol 68:888-98
22. Gomaa AH, Yaar M, Eyada MM et al. (2007) Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol 34:748-53 (Pubitemid 47459684)
23. Graepel R, Fernandes ES, Aubdool AA et al. (2011) 4-Oxo-2-nonenal (4-ONE): evidence of transient receptor potential ankyrin 1-dependent and-independent nociceptive and vasoactive responses in vivo. J Pharmacol Exp Ther 337:117-24
24. Hermes B, Welker P, Feldmann-Boddeker I et al. (2001) Expression of mast cell growth modulating and chemotactic factors and their receptors in human cutaneous scars. J Invest Dermatol 116:387-93 (Pubitemid 32202903)
25. Hua S, Cabot PJ (2010) Mechanisms of peripheral immune-cell-mediated analgesia in inflammation: clinical and therapeutic implications. Trends Pharmacol Sci 31:427-33
26. Huggenberger R, Detmar M (2011) The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc 15:24-32
27. Huggenberger R, Ullmann S, Proulx ST et al. (2010) Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med 207:2255-69
28. Lacey N, Delaney S, Kavanagh K et al. (2007) Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 157: 474-81 (Pubitemid 47256121)
29. Lazaridou E, Apalla Z, Sotiraki S et al. (2010) Clinical and laboratory study of rosacea in northern Greece. J Eur Acad Dermatol Venereol 24:410-4
30. Lazaridou E, Giannopoulou C, Fotiadou C et al. (2011) The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges 9:21-5
31. Liu S, Kapoor M, Denton CP et al. (2009) Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 60:2817-21
32. Ma Q (2010) Labeled lines meet and talk: population coding of somatic sensations. J Clin Invest 120:3773-8
33. Maatta M, Kari O, Tervahartiala T et al. (2006) Tear fluid levels of MMP-8 are elevated in ocular rosacea-treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 244:957-62 (Pubitemid 44184500)
34. Marks R (1973) Histogenesis of the inflammatory component of rosacea. Proc R Soc Med 66:742-5
35. Marks R (2007) The enigma of rosacea. J Dermatol Treat 18:326-8 (Pubitemid 350223201)
36. Marks R, Harcourt-Webster JN (1969) Histopathology of rosacea. Arch Dermatol 100:683-91
37. Mc Aleer MA, Lacey N, Powell FC (2009) The pathophysiology of rosacea. G Ital Dermatol Venereol 144:663-71
38. McAleer MA, Fitzpatrick P, Powell FC (2010) Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol 63:33-9
39. McArthur JC, Stocks EA, Hauer P et al. (1998) Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 55:1513-20
40. Meyer-Hoffert U, Schröder J-M (2011) Epidermal proteases in the patho-genesis of rosacea. J Investig Dermatol Symp Proc 15:16-23
41. Meylan E, Tschopp J, Karin M (2006) Intracellular pattern recognition receptors in the host response. Nature 442:39-44 (Pubitemid 44064203)
42. Millikan L (2003) The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed 2:43-7
43. Morizane S, Yamasaki K, Kabigting FD et al. (2010) Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol 130: 1297-306
44. Mousa SA, Shaqura M, Schaper J et al. (2011) Developmental expression of delta-opioid receptors during maturation of the parasympathetic, sympathetic, and sensory innervations of the neonatal heart: early targets for opioid regulation of autonomic control. J Comp Neurol 519:957-71
45. Muller WA (2011) Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 6:323-44
46. Nakamura K, Rockson SG (2008) Molecular targets for therapeutic lymphangiogenesis in lymphatic dysfunction and disease. Lymphat Res Biol 6:181-9
47. Ogunbiyi S, Chinien G, Field D et al. (2011) Molecular characterization of dermal lymphatic endothelial cells from primary lymphedema skin. Lymphat Res Biol 9:19-30
48. Powell FC (2005) Clinical practice. Rosacea. N Engl J Med 352:793-803
49. Ramelet AA, Perroulaz G (1988) Rosacea: histopathologic study of 75 cases. Ann Dermatol Venereol 115:801-6
50. Roosterman D, Goerge T, Schneider SW et al. (2006) Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev 86:1309-79 (Pubitemid 44523706)
51. Rufli T, Buchner SA (1984) T-cell subsets in acne rosacea lesions and the possible role of Demodex folliculorum. Dermatologica 169:1-5 (Pubitemid 14083507)
52. Scharschmidt TC, Yost JM, Truong SV et al. (2011) Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. Arch Dermatol 147:123-6
53. Schwab VD, Sulk M, Seeliger S et al. (2011) Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 15:53-62
54. Shanler SD, Ondo AL (2007) Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 143:1369-71 (Pubitemid 350146279)
55. Shaw TJ, Kishi K, Mori R (2010) Wound-associated skin fibrosis: mechanisms and treatments based on modulating the inflammatory response. Endocr Metab Immune Disord Drug Targets 10:320-30
56. Smith JR, Lanier VB, Braziel RM et al. (2007) Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 91:226-9 (Pubitemid 46202875)
57. Spiro J, Parker S, Oliver I et al. (1987) Effect of PUVA on plasma and skin immunoreactive alpha-melanocyte stimulating hormone concentrations. Br J Dermatol 117:703-7 (Pubitemid 18067494)
58. Steinhoff M, Buddenkotte J, Shpacovitch V et al. (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1-43 (Pubitemid 40209385)
59. Steinhoff M, Stander S, Seeliger S et al. (2003) Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 139:1479-88 (Pubitemid 37433137)
60. Steinhoff M, Sulk M, Schwab V et al. (2010) Molecular and morphometric characterization of neuroinflammatory and neurovascular changes in the development of rosacea. J Invest Dermatol 130(Suppl 11):S15 (abstract 088)
61. Steinhoff M, Vergnoll N, Young SH et al. (2000) Agonists of proteinase-activated receptor-2 induce inflammation by a neurogenic mechanism. Nat Med 6:151-8 (Pubitemid 30082358)
62. Tuzun Y, Keskin S, Kote E (2010) The role of Helicobacter pylori infection in skin diseases: facts and controversies. Clin Dermatol 28:478-82
63. Wang Y, Liu H, McKenzie G et al. (2010) Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 16:279-85
64. Webster GF (2010) An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis 86:7-15
65. Webster GF (2009) Rosacea. Med Clin North Am 93:1183-94
66. Wilkin J, Dahl M, Detmar M et al. (2002) Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 46:584-7
67. Wilkin J, Dahl M, Detmar M et al. (2004) Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 50:907-12 (Pubitemid 38685771)
68. Wilkin JK (1981) Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol 76:15-8 (Pubitemid 11173530)
69. Wilkin JK (1983) Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 119:211-4 (Pubitemid 13151962)
70. Yamasaki K, Di Nardo A, Bardan A et al. (2007) Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13:975-80 (Pubitemid 47222043)
71. Yamasaki K, Gallo RL (2009) The molecular pathology of rosacea. J Dermatol Sci 55:77-81
72. Yamasaki K, Gallo RL (2011) Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc 15:12-5
73. Yamasaki K, Kanada K, Macleod DT et al. (2011) TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 131:688-97
74. Yamasaki K, Schauber J, Coda A et al. (2006) Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 20:2068-80 (Pubitemid 44953906)